Latest Ratios: P/E Ratio 53.1x · EV/EBITDA 23.3x · ROE 26.8%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.6B | $1.9B | $1.3B | — | — | — | — | — | — |
| Enterprise Value | $2.6B | $1.9B | $1.3B | — | — | — | — | — | — |
| P/E Ratio → | 53.05 | 38.58 | — | — | — | — | — | — | — |
| P/S Ratio | 1.81 | 1.31 | 1.02 | — | — | — | — | — | — |
| P/B Ratio | 12.02 | 8.74 | 8.38 | — | — | — | — | — | — |
| P/FCF | 32.46 | 23.60 | 30.20 | — | — | — | — | — | — |
| P/OCF | 26.13 | 18.99 | 21.67 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.30 | 1.05 | — | — | — | — | — | — |
| EV / EBITDA | 23.30 | 16.86 | — | — | — | — | — | — | — |
| EV / EBIT | 29.15 | 21.10 | — | — | — | — | — | — | — |
| EV / FCF | — | 23.25 | 30.99 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.5% | 19.5% | 19.9% | 19.9% | 20.4% | 20.4% | 20.0% | 20.5% | 20.5% |
| Operating Margin | 6.1% | 6.1% | -5.1% | 3.9% | 5.7% | 3.8% | 4.4% | 4.9% | 4.3% |
| Net Profit Margin | 3.4% | 3.4% | -7.1% | 2.3% | 3.9% | 2.1% | 2.7% | 3.1% | 2.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 26.8% | 26.8% | -83.2% | 35.2% | 54.8% | 27.1% | 42.1% | 45.4% | 21.6% |
| ROA | 13.4% | 13.4% | -29.5% | 9.1% | 14.4% | 7.2% | 9.6% | 11.5% | 8.1% |
| ROIC | 35.8% | 35.8% | -30.4% | 23.0% | 33.7% | 21.3% | 23.6% | 26.4% | — |
| ROCE | 41.5% | 41.5% | -40.6% | 29.5% | 38.7% | 23.6% | 27.0% | 30.6% | 22.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.25 | 1.16 | 0.83 | 1.03 | 0.88 | 2.06 | 0.64 |
| Debt / EBITDA | 0.33 | 0.33 | — | 1.17 | 0.92 | 1.18 | 1.19 | 1.14 | 1.12 |
| Net Debt / Equity | — | -0.13 | 0.22 | 1.14 | 0.82 | 0.75 | 0.78 | 2.05 | 0.61 |
| Net Debt / EBITDA | -0.26 | -0.26 | — | 1.16 | 0.91 | 0.86 | 1.06 | 1.14 | 1.06 |
| Debt / FCF | — | -0.35 | 0.79 | 1.22 | 1.96 | 0.81 | 1.18 | 1.37 | 1.23 |
| Interest Coverage | 133.71 | 133.71 | -19.28 | 14.19 | 26.78 | 18.30 | 14.76 | 14.94 | 13.25 |
Net cash position: cash ($66M) exceeds total debt ($37M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | 1.38 | 1.05 | 0.94 | 1.07 | 1.00 | 1.09 | 1.00 | 1.24 |
| Quick Ratio | 1.11 | 1.11 | 0.77 | 0.67 | 0.70 | 0.71 | 0.72 | 0.66 | 0.82 |
| Cash Ratio | 0.41 | 0.41 | 0.03 | 0.01 | 0.01 | 0.13 | 0.07 | 0.00 | 0.03 |
| Asset Turnover | — | 3.51 | 3.83 | 3.86 | 3.55 | 3.36 | 3.38 | 3.55 | 3.30 |
| Inventory Turnover | 26.91 | 26.91 | 24.27 | 22.81 | 17.45 | 19.06 | 18.45 | 17.93 | 17.33 |
| Days Sales Outstanding | — | 25.60 | 28.87 | 26.96 | 27.24 | 25.46 | 22.70 | 28.34 | 28.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 2.8% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | 160.7% | 87.0% | 106.4% | 54.2% | 114.6% | 156.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 2.6% | — | — | — | — | — | — | — |
| FCF Yield | 3.1% | 4.2% | 3.3% | — | — | — | — | — | — |
| Buyback Yield | 1.1% | 1.5% | 4.4% | — | — | — | — | — | — |
| Total Shareholder Yield | 1.1% | 1.5% | 7.2% | — | — | — | — | — | — |
| Shares Outstanding | — | $63M | $62M | $61M | $61M | $61M | $61M | $61M | $61M |
Margin Compression from PBMs
Based on current market data, Guardian Pharmacy Services trades at a forward P/E of 33.58, which suggests that investors are pricing in significant future earnings expansion relative to the broader healthcare distribution sector, despite the company's historically volatile net income and thin operating margins.
The current valuation multiples appear to reflect a 'complexity premium' associated with the company's decentralized ALF-focused model rather than traditional pharmacy distribution. However, the PEG ratio of 2.89 indicates that the market may be overestimating the sustainability of current growth rates, warranting caution regarding the company's ability to maintain these multiples if earnings volatility persists.
As reported in recent financial statements, ROIC has fluctuated significantly from a peak of 18.4% in 2025Q4 to 6.7% in 2026Q1, indicating that the company's ability to compound capital is heavily dependent on the timing of acquisitions and the successful integration of local pharmacy partners.
The inconsistency in ROIC suggests that the decentralized operating model may struggle to achieve consistent economies of scale, as the capital base expands faster than the underlying operational returns. Investors should monitor whether the company can stabilize these returns above its cost of capital as the footprint matures.
According to quarterly filings, the cash conversion cycle has tightened to 5 days as of 2026Q1, reflecting a more disciplined approach to managing inventory and receivables compared to the operational inefficiencies observed in earlier periods of the company's rapid expansion phase.
The reduction in the cash conversion cycle is a positive indicator of improved operational leverage, though it remains sensitive to the payment cycles of assisted living facility clients. Sustaining this efficiency is critical, as any slippage in DSO could quickly erode the company's already thin liquidity buffers.
Based on the provided balance sheet data, Guardian Pharmacy Services has successfully reduced its debt-to-equity ratio to 0.16 as of 2026Q1, a marked improvement from the 1.33 level seen in 2024Q2, which significantly de-risks the firm against potential interest rate volatility.
This conservative capital structure provides the company with substantial 'dry powder' for future bolt-on acquisitions, distinguishing it from more levered peers in the healthcare services space. The current interest coverage ratio of 114.77 suggests that debt service is currently well-supported, providing a stable foundation for long-term strategic initiatives.
The most commonly misapplied metric for Guardian Pharmacy Services is the standard P/E ratio, which obscures the company's true earning power by failing to account for the significant non-operating expenses and stock-based compensation that frequently distort net income in this specific business model.
Analysts should instead focus on EV/EBITDA or free cash flow yields to better capture the underlying operational cash generation of the decentralized pharmacy hubs. Relying on P/E in this context risks misinterpreting the company's valuation by ignoring the capital-intensive nature of its growth and the accounting nuances of its partnership structure.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GRDN stock.
Guardian Pharmacy Services, Inc.'s current P/E ratio is 53.1x. The historical average is 38.6x. This places it at the 100th percentile of its historical range.
Guardian Pharmacy Services, Inc.'s current EV/EBITDA is 23.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.9x.
Guardian Pharmacy Services, Inc.'s return on equity (ROE) is 26.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 21.2%.
Based on historical data, Guardian Pharmacy Services, Inc. is trading at a P/E of 53.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Guardian Pharmacy Services, Inc. has 19.5% gross margin and 6.1% operating margin.
Guardian Pharmacy Services, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.